其他
Relay Therapeutics(RLAY)04-24 04:25
$Relay Therapeutics(RLAY)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-046910 Act: 34 Size: 6 MB 网页链接
简介:Relay Therapeutics, Inc.于2015年5月4日在特拉华州注册成立。该公司是一家临床阶段的精密药物公司,致力于转变药物发现过程,最初的重点是增强靶向肿瘤学中的小分子治疗发现。该公司建立在对蛋白质运动以及这种动态行为与蛋白质功能之间无与伦比的洞察力之上。该公司的Dynamo平台集成了一系列先进的实验和计算方法,使该公司可以将对蛋白质结构和运动的理解应用于药物开发。该公司正在开发其主要候选产品RLY-4008和RLY-1971,并为PI3Kα选择性突变体计划(RLY-PI3K1047计划)开发候选药物,以治疗晚期实体瘤患者。
今开:6.8 | 昨收:6.85 |
最高:7.09 | 最低:6.78 |
涨停价: | 跌停价: |
总市值:921227238 |
Relay Therapeutics(RLAY)04-24 04:25
$Relay Therapeutics(RLAY)$ ARS Annual Report to Security Holders Accession Number: 0000950170-24-046910 Act: 34 Size: 6 MB 网页链接
Relay Therapeutics(RLAY)04-30 08:35
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-050147 Size: 5 KB 网页链接
Relay Therapeutics(RLAY)04-30 08:35
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-050151 Size: 4 KB 网页链接
Relay Therapeutics(RLAY)05-03 04:15
$Relay Therapeutics(RLAY)$ 8-K Current report, items 2.02 and 9.01 Accession Number: 0000950170-24-052110 Act: 34 Size: 280 KB 网页链接
Relay Therapeutics(RLAY)06-13 04:15
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072426 Size: 6 KB 网页链接
Relay Therapeutics(RLAY)06-06 08:15
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069558 Size: 5 KB 网页链接
Relay Therapeutics(RLAY)06-06 08:05
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069555 Size: 5 KB 网页链接
Relay Therapeutics(RLAY)06-06 20:05
$Relay Therapeutics(RLAY)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0000950170-24-069674 Act: 34 Size: 34 MB 网页链接
Relay Therapeutics(RLAY)04-24 04:15
$Relay Therapeutics(RLAY)$ DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material Accession Number: 0000950170-24-046897 Act: 34 Size: 3 MB 网页链接
Relay Therapeutics(RLAY)03-30 04:25
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-038655 Size: 4 KB 网页链接
SeekingBiotech02-17 22:55
小分子Relay
暂停了一个候选分子CDK2,和ERa degrader.蛋白降解 。
前者专利。WO2024035830 。$Relay Therapeutics(RLAY)$查看全文
氨基观察2023-07-14 11:54
一念一菩提2023-07-12 22:01
$Relay Therapeutics(RLAY)$ Ai制药板块联动了,好事查看全文
氨基观察2023-07-12 15:51
Spica2023-05-05 09:48
回复@鉴兮: 之前写过一篇文章简介$Schrodinger(SDGR)$ ,网页链接查看全文
丰硕创投2023-04-27 08:55
1281字5图,阅读大约需要4分钟。
文章首发于丰硕创投,欢迎朋友圈与微信转发。
公众号及其他平台转载请后台留言。
AI制药公司Relay近日在AACR 2023会议上披露了PI3Kα抑制剂RLY-2608初步临床有效性数据的信号,看完官网上披露的PPT数据后,基本判定这款药没有继续开发下去的必要了。 ...查看全文
Spica2023-04-25 09:22
写了一篇新的文章展开分析了我对$Relay Therapeutics(RLAY)$ 此次AACR公布PI3Kα抑制剂,RLY-2608的数据思考,以及对Relay平台的思考。网页链接。新药开发历经艰辛,实属不易!但这也是人类想要不断了解自身,一定程度对抗自然,让自己更健康更长寿而持...查看全文
Spica2023-04-23 11:28
回复@tiger-in-motion: 抱歉迟回复。$Relay Therapeutics(RLAY)$ 的首个PI3Kα的变构、泛突变和异型选择性研究抑制剂RLY-2608目前安全性理想,选择性好,但有效性没体现出来,该药物尚未达到最大耐受剂量,公司计划加大剂量。另外还有一个备选的泛突变型、同种型选择性PI3Kα抑制剂,RLY-5836,化...查看全文
chuminhua2023-04-20 13:03
4月19日,Relay Therapeutics $Relay Therapeutics(RLAY)$ 报告了其泛突变选择性口服 PI3Kα 抑制剂 RLY-2608 的早期数据,表明该药的多个剂量都在乳腺癌患者中实现了选择性靶点参与,并且还具有“良好的”初始安全性。 然而,投资者对在美国癌症研究协会 (AACR) 会议上公布的疗效结果感到失望。
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-072426 Size: 6 KB 网页链接
$Relay Therapeutics(RLAY)$ 8-K Current report, items 7.01, 8.01, and 9.01 Accession Number: 0000950170-24-069674 Act: 34 Size: 34 MB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069558 Size: 5 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069559 Size: 5 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069560 Size: 5 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069554 Size: 5 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069555 Size: 5 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069553 Size: 9 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069556 Size: 5 KB 网页链接
$Relay Therapeutics(RLAY)$ 4 Statement of changes in beneficial ownership of securities Accession Number: 0000950170-24-069557 Size: 5 KB 网页链接